Law360, New York (February 04, 2009, 12:00 AM ET) -- Three classes of buyers of the testosterone supplement AndroGel have hit several drugmakers with separate actions claiming their patent settlements over the drug thwarted competition and denied the buyers cheaper generics.
Two of the proposed class actions were filed on Tuesday in the U.S. District Court for the Central District of California. The first private action was filed on Monday in the same court, on the same day the state of California and the Federal Trade Commission launched their own suit in that court making similar...
3 Private Actions Fight AndroGel Reverse Payments
To view the full article, take a free trial now.
